Compare STOK & BAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | STOK | BAND |
|---|---|---|
| Founded | 2014 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.3B |
| IPO Year | 2019 | 2017 |
| Metric | STOK | BAND |
|---|---|---|
| Price | $32.29 | $47.52 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 10 | 4 |
| Target Price | ★ $39.20 | $24.50 |
| AVG Volume (30 Days) | 721.3K | ★ 1.1M |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.73 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $184,420,000.00 | ★ $204,113,000.00 |
| Revenue This Year | N/A | $15.16 |
| Revenue Next Year | $77.49 | $6.18 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 404.50 | 25.26 |
| 52 Week Low | $18.20 | $12.50 |
| 52 Week High | $40.22 | $79.08 |
| Indicator | STOK | BAND |
|---|---|---|
| Relative Strength Index (RSI) | 54.16 | 41.00 |
| Support Level | $30.34 | $14.03 |
| Resistance Level | $34.62 | $77.53 |
| Average True Range (ATR) | 1.70 | 3.52 |
| MACD | 0.04 | 0.37 |
| Stochastic Oscillator | 69.72 | 40.03 |
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
Bandwidth Inc is cloud-based communications platform-as-a-service (CPaaS) provider that enables enterprises to create, scale and operate voice or messaging communications services across any mobile application or connected device. Company earns revenue through the sale of communications services offered through Application Programming Interface software solutions to enterprise customers. The majority of its revenue is generated from usage-based fees that includes voice communication and messaging communication that traverse the platform and network.